Journal
WOMENS HEALTH
Volume 2, Issue 1, Pages 11-21Publisher
SAGE PUBLICATIONS LTD
DOI: 10.2217/17455057.2.1.11
Keywords
Abraxane (TM); breast cancer; chemotherapy; docetaxel; paclitaxel; Taxol (TM); Taxotere (TM)
Categories
Ask authors/readers for more resources
Paclitaxel, a chemotherapeutic drug isolated from the Pacific yew, was approved for the treatment of metastatic breast cancer in 1994 and remains one of the most important agents in the treatment of patients with this disease. It is currently approved for the adjuvant treatment of node-positive breast cancer, administered sequentially after a standard doxorubicin-containing regimen, and for metastatic disease after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. In this article, data on the pharmacology, clinical efficacy and safety of paclitaxel for the treatment of breast cancer will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available